Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals…
Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body count. Here is where he says the smart money is quietly moving…
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may…
Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping…
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are…
Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but…
European stocks are having their loudest year in a decade, and the Vanguard FTSE Europe ETF (NYSEARCA:VGK) is the vehicle most retail investors will consider. VGK trades around $90, up 18% over…
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully…
Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector…
June is shaping up as a stock-picker’s month. Spring volatility has settled, and contrarian investors are scanning the wreckage for quality names trading well off their highs with identifiable recovery catalysts. Three…
Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date…
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted…
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults,…
Live Updates SpaceX IPO Details, Uber Layoffs10:42am ETSpaceX has set its IPO price target at $135 per share, a figure that would place the company’s valuation in line with the record-setting numbers…
Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling…
